AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Spray to prevent flu FDA approves AstraZeneca's FluMist vaccine
Written byMarket Vision
Friday, Sep 20, 2024 8:00 pm ET1min read
The U.S. FDA approved AstraZeneca's (AZN.US) FluMist, a nasal spray vaccine, for the prevention of influenza disease caused by A and B influenza viruses in people aged 2 to 49. FluMist is the first influenza vaccine available for eligible patients to self-administer or for caregivers to administer.
Market Vision
Navigating the Stock Market Through Visual Content
Latest Articles
Intel Courts Apple for Investment in High-Stakes Chip Revival
Sep.24 2025
Meta's High-Stakes Glasses Gambit: Hypernova Could Redefine Reality Labs' $70 Billion Bet
Sep.16 2025
Oracle's Stock Soars, Propelling Ellison Briefly Past Musk in "World's Richest" Race
Sep.10 2025
Apple's 2025 Event: A Slimmer iPhone and Subtle Shifts in a High-Stakes Market
Sep.09 2025
Here Are What You Need To Know About Apple's 'Awe Dropping' Event
Sep.09 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet